Plain-English translation of NCT05418010 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether natalizumab (Tyruko®), a medication already approved to treat MS, works better when given very early—within just 2 weeks of your first symptoms. The study wants to see if starting treatment this early can help repair the nerve insulation damage that MS causes, rather than waiting weeks or months for a confirmed diagnosis.
MS diagnosis can take a long time, which delays treatment and allows more nerve damage to happen. This trial is testing whether this medication can be safely and effectively given much earlier, potentially protecting your nerves before permanent damage occurs.
You likely qualify if…
You likely don't qualify if…
If you're in the treatment group, you'll receive the medication through an IV infusion every 4 weeks for 6 months total. If you're in the placebo group, you'll receive a dummy infusion for the first 2 months, then switch to the active medication for the remaining time. Throughout the study, you'll have regular clinic visits and brain MRI scans to check if the early treatment helps your nerves heal.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United Kingdom